IDEFIRIX^®

The marketing registration status of the products varies depending on countries in which they are approved.

IDEFIRIX^® (imlifidase)

IDEFIRIX^® (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is conditionally authorized by the European Commission (EC) for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch test against an available deceased donor. The use of IDEFIRIX should be reserved for patients who are unlikely to be transplanted under the available kidney allocation system, including prioritization programs for highly sensitized patients.

Read the information on IDEFIRIX^® on the European Medicines Agency’s website